Intact Investment Management Inc. Cuts Stock Position in Amgen Inc. $AMGN

Intact Investment Management Inc. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,400 shares of the medical research company’s stock after selling 3,200 shares during the quarter. Intact Investment Management Inc.’s holdings in Amgen were worth $6,321,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC purchased a new position in Amgen during the second quarter valued at $27,000. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen during the 2nd quarter worth about $32,000. Quaker Wealth Management LLC lifted its stake in Amgen by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares in the last quarter. Finally, Nvwm LLC boosted its holdings in Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after buying an additional 134 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.7%

Shares of AMGN opened at $344.75 on Monday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $349.98. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The stock has a fifty day simple moving average of $332.07 and a two-hundred day simple moving average of $307.69. The company has a market capitalization of $185.64 billion, a PE ratio of 26.64, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the firm posted $5.58 earnings per share. Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 73.57%.

Analysts Set New Price Targets

A number of brokerages have commented on AMGN. Piper Sandler increased their target price on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. UBS Group raised Amgen to a “strong-buy” rating in a research note on Wednesday, January 7th. DZ Bank raised their price objective on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Truist Financial upped their target price on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average target price of $339.24.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.